Generics & Biosimilars | Association for Accessible Medicines
In the News - View AAM CEO Dan Leonard's blog on the essential role generic drugs play during COVID-19
Learn More
Close
  • My Prescription for Savings. It’s time for Congress to take meaningful action to lower prescription drug costs with the Prescription for Savings. Patients win when market-based competition from FDA-approved generics and biosimilars deliver savings at the pharmacy counter.
    AAM’s Recommendations to #SecureOurMeds
    Congress can take meaningful action to lower prescription drug costs. AAM’s Prescription for Savings outlines several solutions to secure patient access to generics and biosimilar medicines.
    View Solutions
  • Dr. Janet Woodcock, Acting Commissioner of the Food and Drugs Administration at Access! 2021 - AAM Annual Meeting
    FDA Acting Commissioner Janet Woodcock to Speak at Access!
    An inspired choice to keynote this year’s conference, Dr. Woodcock is sure to bring new ideas and fresh insights to the table as we move into a critical time for our industry.
    Learn More
  • SecureOurMeds
    Congress Can Help to Secure Our Meds
    Generic and biosimilar medicines are essential to treating millions of patients. Together, we can take steps to secure patient access no matter what challenges may arise.
    Learn More
  • Secure Our Meds
    Plan to Secure Our Medicines
    The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to #SecureOurMeds. We already produce billions of doses domestically and our plan ensures continued patient access through COVID and beyond.
    Watch Video
  • Dan Leonard, AAM CEO and President, by his desk
    While We Await Vaccine Progress, We Can Trust in Generic Drugs
    Read AAM CEO Dan Leonard's article on the essential role generic drugs play during the COVID-19, while we await a vaccine.
    Read Blog
  • Interactive Savings Map 2020
    Health Care Savings, State by State
    The average state saved $6.1 billion from the use of generic drugs in 2019. How much did your state save?
    Read Blog
  • AAM Blueprint U.S. Supply Chain
    Securing the U.S. Rx Supply Chain
    The generic drug industry in the U.S. can expand domestically to increase national security, lessen dependence on any single country and create more jobs. Learn about our plan.
    View Blueprint
  • ""
    Industry Response to COVID-19
    The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.
    Learn More

Working to leave a positive impact on...

Industry Industry We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More
People People We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More
Policy Policy We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Who We Are

Recent Updates

Association for Accessible Medicines

601 New Jersey Ave NW, Suite 850
Washington DC 20001

 

202.249.7100
info@accessiblemeds.org

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.